Work

76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.356

Authors: A. Oaknin, L. Gilbert, A. Tinker, J. Brown, C. Mathews, J.Z. Press, R. Sabatier, D. O'Malley, V. Samouelian, V. Boni, L. Duska, S. Ghamande, P. Ghatage, R. Kristeleit, C. Leath, X. Han, S. Kumar, T. Duan, E. Im, B. Pothuri

Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, McGill University Health Centre, Research Institute of the McGill University Health Centre, BC Cancer Agency, Levine Cancer Institute, Women & Infants Hospital of Rhode Island, Swedish Medical Center, Aix-Marseille Université, Institut Paoli-Calmettes, The Ohio State University, Centre Hospitalier de l’Université de Montréal, Université de Montréal, HM Hospitales, Hospital Universitario HM Sanchinarro, University of Virginia Medical Center, University of Virginia, Augusta University, University of Calgary, Guy's Hospital, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, GlaxoSmithKline (United States), NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3202571026

FWCI: 0.409

Cites:

Cited by: 6

Related to: 10